Skip to main content

Moderate to Severe Glabellar Lines

3
Pipeline Programs
4
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Galderma
GaldermaTX - Dallas
1 program
1
QM1114-DPPhase 31 trial
Active Trials
NCT05463965Completed605Est. Jun 2023
EuBiologics
EuBiologicsKorea - Seoul
1 program
1
ATGC-100Phase 1/21 trial
Active Trials
NCT03970876Completed60Est. Dec 2019
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
AGN-151586Phase 11 trial
Active Trials
NCT06151561Completed24Est. Apr 2024
Ipsen
IpsenChina - Tianjin
3 programs
Botulinum toxin type APHASE_31 trial
IPN10200PHASE_31 trial
IPN10200PHASE_31 trial
Active Trials
NCT02353871Completed185Est. Aug 2015
NCT07427797Recruiting300Est. Jul 2027
NCT07435428Recruiting1,300Est. Oct 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
IpsenIPN10200
IpsenIPN10200
GaldermaQM1114-DP
IpsenBotulinum toxin type A
EuBiologicsATGC-100
AbbVieAGN-151586

Clinical Trials (6)

Total enrollment: 2,474 patients across 6 trials

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Start: Feb 2026Est. completion: Jul 2027300 patients
Phase 3Recruiting

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Start: Feb 2026Est. completion: Oct 20281,300 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Start: Jul 2022Est. completion: Jun 2023605 patients
Phase 3Completed
NCT02353871IpsenBotulinum toxin type A

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Start: Jan 2015Est. completion: Aug 2015185 patients
Phase 3Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Start: Apr 2019Est. completion: Dec 201960 patients
Phase 1/2Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Start: Jan 2024Est. completion: Apr 202424 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 2,474 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.